Kimia Biosciences Ltd
About
[
edit
]
Laurel Organics Ltd. is engaged in manufacture of bulk drugs such as Ciprofloxacin and Norfloxacin.
[
add key points
]
- Market Cap ₹ 194 Cr.
- Current Price ₹ 41.0
- High / Low ₹ 64.4 / 19.5
- Stock P/E 37.0
- Book Value ₹ 4.01
- Dividend Yield 0.00 %
- ROCE 9.19 %
- ROE 15.9 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 22.29% CAGR over last 5 years
Cons
- Stock is trading at 10.22 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company might be capitalizing the interest cost
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
18.15 | 22.16 | 32.65 | 20.20 | 18.91 | 25.59 | 32.04 | 27.40 | 21.25 | 24.85 | 37.50 | 34.35 | |
18.81 | 21.23 | 30.65 | 18.65 | 18.96 | 25.03 | 29.54 | 26.68 | 20.59 | 22.14 | 33.63 | 32.47 | |
Operating Profit | -0.66 | 0.93 | 2.00 | 1.55 | -0.05 | 0.56 | 2.50 | 0.72 | 0.66 | 2.71 | 3.87 | 1.88 |
OPM % | -3.64% | 4.20% | 6.13% | 7.67% | -0.26% | 2.19% | 7.80% | 2.63% | 3.11% | 10.91% | 10.32% | 5.47% |
Other Income | 0.50 | 0.01 | 0.01 | 0.82 | 1.63 | 0.56 | 0.15 | 0.34 | -0.08 | 0.37 | 1.06 | 0.55 |
Interest | 0.02 | 0.27 | 0.18 | 0.15 | 1.40 | 0.42 | 0.45 | 0.57 | 1.08 | 0.70 | 0.91 | 0.77 |
Depreciation | 0.34 | 0.27 | 0.27 | 0.28 | 0.28 | 0.37 | 0.43 | 0.41 | 0.45 | 0.40 | 0.41 | 0.50 |
Profit before tax | -0.52 | 0.40 | 1.56 | 1.94 | -0.10 | 0.33 | 1.77 | 0.08 | -0.95 | 1.98 | 3.61 | 1.16 |
Tax % | 11.54% | 0.00% | 0.00% | 0.00% | 50.00% | 0.00% | 0.00% | 0.00% | 16.84% | 0.00% | 0.00% | 63.79% |
Net Profit | -0.45 | 0.40 | 1.56 | 1.94 | -0.05 | 0.32 | 1.77 | 0.08 | -0.79 | 1.98 | 3.61 | 0.43 |
EPS in Rs | -0.61 | 0.54 | 2.11 | 1.33 | -0.03 | 0.14 | 0.43 | 0.02 | -0.17 | 0.42 | 0.76 | 0.09 |
Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes |
Profit & Loss
Figures in Rs. Crores
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
8 | 8 | 8 | 9 | 12 | 6 | 2 | 0 | 1 | 76 | 94 | 106 | 118 | |
7 | 6 | 6 | 8 | 10 | 7 | 4 | 4 | 2 | 74 | 88 | 102 | 109 | |
Operating Profit | 2 | 1 | 2 | 1 | 2 | -0 | -2 | -3 | -1 | 2 | 6 | 4 | 9 |
OPM % | 19% | 19% | 21% | 12% | 16% | -5% | -110% | -1,779% | -56% | 3% | 6% | 4% | 8% |
Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 2 |
Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 3 | 3 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 |
Profit before tax | 1 | 1 | 1 | 0 | 1 | -1 | -2 | -4 | -1 | 2 | 4 | 1 | 6 |
Tax % | 10% | 4% | 3% | 11% | 6% | 1% | -1% | -0% | 8% | -4% | -1% | -13% | |
Net Profit | 1 | 1 | 1 | 0 | 1 | -1 | -2 | -4 | -1 | 2 | 4 | 1 | 5 |
EPS in Rs | 0.97 | 0.91 | 1.33 | 0.54 | 1.71 | -1.06 | -2.30 | -5.48 | -1.26 | 2.26 | 2.64 | 0.30 | 1.10 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 30% |
5 Years: | 127% |
3 Years: | 318% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 22% |
3 Years: | 56% |
TTM: | 147% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -7% |
1 Year: | 78% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 16% |
Balance Sheet
Figures in Rs. Crores
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 2 | 2 | 5 | 5 | |
Reserves | -8 | -7 | -6 | -6 | -5 | -6 | -7 | -11 | -12 | -2 | 2 | 9 | 14 |
Borrowings | 4 | 3 | 2 | 2 | 1 | 0 | 1 | 7 | 14 | 33 | 31 | 34 | 40 |
2 | 3 | 2 | 3 | 2 | 3 | 4 | 1 | 3 | 25 | 31 | 38 | 45 | |
Total Liabilities | 5 | 6 | 5 | 7 | 6 | 6 | 5 | 4 | 12 | 58 | 65 | 86 | 104 |
3 | 4 | 3 | 3 | 4 | 4 | 3 | 3 | 7 | 13 | 16 | 18 | 19 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 2 | 6 | 8 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
2 | 2 | 2 | 3 | 2 | 2 | 1 | 1 | 2 | 43 | 48 | 62 | 77 | |
Total Assets | 5 | 6 | 5 | 7 | 6 | 6 | 5 | 4 | 12 | 58 | 65 | 86 | 104 |
Cash Flows
Figures in Rs. Crores
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 1 | 1 | 2 | 1 | 1 | 0 | -6 | -1 | -7 | -3 | 0 | |
0 | 0 | -0 | -1 | -1 | -0 | 0 | -0 | -6 | -2 | -2 | -9 | |
-1 | -1 | -1 | -1 | -1 | -0 | -0 | 6 | 7 | 10 | 4 | 8 | |
Net Cash Flow | 0 | 0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | 0 | -0 | 0 |
Ratios
Figures in Rs. Crores
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
ROCE % | 43% | 36% | 44% | 22% | 46% | -25% | -127% | -188% | -10% | 10% | 17% | 9% |
Debtor Days | 41 | 41 | 59 | 80 | 41 | 22 | 56 | 173 | 20 | 141 | 113 | 128 |
Inventory Turnover | 19.25 | 15.57 | 21.89 | 20.44 | 19.17 | 23.50 | 16.53 | 5.20 | 1.58 | 12.02 | 5.73 | 4.58 |
Documents
Add documentRecent announcements
- Bagging Of Permission To Manufacture New Active Pharmaceutical Ingredient For Sale Or For Distribution. 22 Feb
- Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Feb
- Outcome Of Board Meeting Held On Thursday, February 11, 2021 11 Feb
- Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Feb
- Board Meeting Intimation for Regulation 29 Of SEBI (LODR) Regulations, 2015 -Intimation Of Meeting Of Board Of Directors 1 Feb
View all